##  [Compliance](/esg/ethics-risk-and-compliance/compliance "Compliance") 

 At Novartis, we are committed to upholding high standards of ethical conduct and maintaining the trust of our patients and stakeholders. Our vision is to be the most valued and trusted medicines company in the world, and this requires consistent and rigorous adherence to ethical business practices.

Our Global Ethics, Risk & Compliance (ERC) function plays a critical role in designing and maintaining our robust compliance management system. Each Novartis Unit is responsible for implementing and sustaining the program, with a focus on ensuring that all employees act with integrity and comply with applicable laws and regulations.

We recognize that accountability is key to maintaining ethical standards across all our local country organizations. As part of our standard business reviews, management conducts regular reviews that include integrity and compliance updates to ensure that our commitment to ethical business practices remains unwavering. By prioritizing compliance and ethical behavior, we are confident that we can continue to provide the best possible care for patients worldwide and achieve our vision of becoming the most valued and trusted medicines company in the world.



 



 [ 

 ![Two doctors shaking hands](/sites/novartis_com/files/styles/cards_50_50/public/2023-10/two-doctors-shaking-hands.jpg.webp?itok=MOEetWF- "Two doctors shaking hands") 

 

###  Doing Business Ethically 

The new Policy Framework reinforces our commitment to maintain high standards of ethical business conduct and to not tolerate any form of bribery or corruption.

 

 

 ](/esg/ethics-risk-and-compliance/compliance/doing-business-ethically) [ 

 ![Men working on a document](/sites/novartis_com/files/styles/cards_50_50/public/2023-10/men-hand-holding-a-pen.jpg.webp?itok=6MCUxyUg "Men working on a document") 

 

###  Anti-Bribery report 

Working with Norges Bank Investment Management (NBIM), we helped develop an anti-bribery reporting standard for the pharmaceuticals industry that was issued in 2022. We report against this standard.

 

 

 ](/esg/ethics-risk-and-compliance/compliance/anti-bribery-report) 





 

 

 



 

 [Conflicts of Interest Policy (PDF 0.3 MB)](/sites/novartis_com/files/conflicts-of-interest-policy.pdf "Conflicts of Interest Policy (PDF 0.3 MB)") 



 [Our commitment to ethical and responsible use of AI](/esg/ethics-risk-and-compliance/compliance/our-commitment-ethical-and-responsible-use-artificial-intelligence "Our commitment to ethical and responsible use of AI") 



 [Positions](/esg/reporting/positions "Positions")